https://www.alzheimerssupport4u.com/

Alzheimer's Support, LLC, Silver Springs, FL (2026)

06/19/2026

Can A Copper Drug Clear Out Toxic Proteins and Restore Memory in Alzheimer’s Disease?

This new research feels like a small light turning on in a very dark room. It comes from a preclinical study shared by Monash University, and it offers something caregivers rarely get enough of: a reason to breathe a little easier, even if just for a moment.
A team of scientists in Australia has discovered something quietly remarkable. In a laboratory study, a copper based drug called Cu(ATSM) helped the brain do something it struggles to do in Alzheimer’s disease: clear out toxic proteins and restore memory.
You can read the original report here: https://vist.ly/58b8t (medicalxpress.com in Bing)
Why this matters so deeply
Alzheimer’s disease slowly fills the brain with harmful proteins called amyloid beta. In a healthy brain, these proteins are washed away through a tiny but powerful system at the blood–brain barrier. Think of it as the brain’s cleaning pump.
But in Alzheimer’s, that pump weakens. Waste builds up. Memory fades. Families watch someone they love slip further away.
This study shows that Cu(ATSM) may help repair that pump. When the pump works again, the brain can finally breathe.
What the researchers found
In mice bred to develop Alzheimer’s like symptoms, the copper drug did three extraordinary things:
• It increased the brain’s waste clearing pump (P gp) by more than 24%.
• It reduced toxic amyloid beta proteins by 42%.
• It improved long term spatial memory by nearly 44%.
These aren’t small changes. They suggest the brain isn’t as helpless as Alzheimer’s makes it seem. When given the right support, it can fight back.
Why copper?
Copper is a natural metal the brain uses for energy, protection, and repair. Cu(ATSM) is a special form of copper that can cross into the brain and deliver copper exactly where it’s needed.
It has already been tested for safety in other diseases like Parkinson’s and ALS, which means it may move into human Alzheimer’s trials more quickly.
A hopeful possibility
Researchers believe the drug may help in two ways:
• Repairing the blood–brain barrier, allowing the brain to flush out toxic proteins
• Empowering microglia, the brain’s gentle immune cells, to clean up harmful plaques
They are still studying exactly how the proteins leave the brain, but the early signs are promising.
What this means for caregivers and families
This is not yet a treatment available to the public. It is early research — hopeful, but still in the preclinical stage.
And yet, for families living with Alzheimer’s, hope matters. Even small steps forward matter. Every discovery like this reminds us that the story is not over, and that brilliant minds around the world are working tirelessly to ease the suffering of millions.
A gentle, human takeaway
Alzheimer’s can feel like a thief, stealing memories, moments, and the person you love. Studies like this remind us that science is still fighting for them. That the brain is still fighting for them. And that somewhere in a lab, someone is working late into the night because they believe your loved one deserves more time, more clarity, more connection.
This copper based drug is not a cure. But it is a sign, a warm, steady sign, that healing may be possible in ways we are only beginning to understand.

06/18/2026

ADHD and Alzheimer’s
What Researchers Are Learning About the Possible Connection

There is growing interest in how lifelong brain patterns may influence cognitive health in later life, and one question researchers are exploring is whether ADHD and Alzheimer’s disease share any meaningful connection. My Alz Team recently published an article that brings together what scientists know so far, and it offers a thoughtful look at how these two conditions may intersect. You can read the original piece at https://vist.ly/586qk.
ADHD is a neurodevelopmental condition that affects attention, planning, organization, and impulse control. Alzheimer’s disease affects memory, reasoning, and the ability to navigate daily life. Because both conditions involve changes in the brain systems responsible for attention and memory, researchers have begun studying whether people diagnosed with ADHD may face a higher likelihood of developing dementia as they age.
Several long term studies suggest that adults with ADHD appear more likely to receive a later diagnosis of dementia, including Alzheimer’s disease. One study followed more than one hundred thousand adults for seventeen years and found a noticeable pattern. Another study showed a similar trend, although the risk shifted when other mental health conditions such as depression or anxiety were considered. This tells us the relationship is layered and influenced by many factors.
Scientists are exploring several possible explanations. Some believe there may be shared genetic pathways. Others point to the frontal lobe, the region of the brain involved in attention and planning, which is affected in both ADHD and Alzheimer’s. Lifestyle patterns that sometimes accompany unmanaged ADHD, such as disrupted sleep or chronic stress, may also play a role over time.
One reassuring finding is that current research shows no evidence that ADHD medications increase the risk of Alzheimer’s or dementia. The long term effects of treatment are still being studied, but nothing so far suggests that medication contributes to cognitive decline.
For individuals living with ADHD, or caring for someone who is, this information does not mean Alzheimer’s is inevitable. Instead, it highlights the importance of steady routines, brain healthy habits, and open conversations with healthcare providers. It also reminds us that symptoms such as forgetfulness or difficulty concentrating can overlap between the two conditions, which makes careful evaluation essential.
MyAlzTeam’s article offers a helpful starting point for understanding this emerging area of research. Their work encourages caregivers and families to stay informed, stay curious, and stay connected to reliable sources of information. You can explore the full article at https://vist.ly/586qk (myalzteam.com in Bing).

06/17/2026

When Words Fade: How Touch, Presence, and Nonverbal Connection Support People Living With Alzheimer’s

When someone you love is living with Alzheimer’s disease, communication can feel like a door that keeps closing. Words slip away. Sentences trail off. Conversations that once felt effortless now feel confusing or one sided.
But here’s something caregivers often need to hear:
Connection does not disappear when language does. It simply changes.
Research and caregiver experience show that touch, tone, facial expression, and presence remain powerful ways to communicate, even in the later stages of Alzheimer’s.
Below is a simple, compassionate guide to understanding why nonverbal communication matters, and how you can use it to stay connected with the person you love.
Why Nonverbal Communication Still Works
Even as Alzheimer’s affects memory and language, many parts of the brain that process emotion, rhythm, tone, and touch remain active longer.
The National Institute on Aging notes that people with Alzheimer’s often rely more on nonverbal cues as verbal abilities decline: https://vist.ly/5724v (nia.nih.gov in Bing)
The Alzheimer’s Association emphasizes that your facial expression, body language, and tone of voice can communicate safety and comfort even when words don’t land: https://vist.ly/5724y (alz.org in Bing)
Emerging research supports this. A medRxiv review of nonverbal communication tools for dementia care found that touch, gesture, and emotional tone remain meaningful channels of connection: https://vist.ly/5725a
In other words: Your presence still reaches them.
How Touch Helps
A gentle hand on the shoulder. Holding hands during a walk. A soft hug when they seem unsure.
Touch can:
• Reduce anxiety
• Provide grounding
• Communicate reassurance
• Strengthen emotional connection
Even when words are confusing, your touch can say “I’m here with you.”
How Your Tone of Voice Helps
People with Alzheimer’s often respond more to how something is said than what is said.
Try:
• Speaking slowly
• Using a warm tone
• Keeping your voice calm
• Matching your tone to your message
A soothing tone can help prevent frustration and reduce agitation.
How Your Presence Helps
Sometimes the most powerful communication is simply being there.
Sitting together. Listening to music. Sharing a quiet moment. Looking at a photo album.
These moments build connection without needing conversation.
The CDC notes that while Alzheimer’s affects memory and language, emotional memory often remains: https://vist.ly/57254 (cdc.gov in Bing)
They may not remember the details, but they remember how you make them feel.
Practical Tips for Caregivers
• Approach from the front so they see you coming and to the side so it does not feel like an attack
• Make eye contact
• Smile gently
• Use simple gestures
• Keep your body language relaxed
• Offer your hand instead of giving instructions
• Use familiar objects or photos to guide interactions
• Match your facial expression to your message
More caregiver resources: https://vist.ly/57258 (alzheimers.gov in Bing)
You Are Still Reaching Them
Even when words fade, connection remains possible.
Your touch, your voice, your presence, these are powerful tools. You are not failing. You are communicating in a new language, one built on emotion, safety, and love.
And that still matters.

06/16/2026

Alzheimer’s in America: How Age, Gender, State Demographics, and Dementia Types Shape Today’s Landscape

The newest national Alzheimer’s data paints a picture that is both sobering and clarifying. Women continue to be diagnosed at older ages than men, states with older populations carry a heavier burden, and Alzheimer’s remains the leading cause of dementia even when compared with all other dementias combined. These patterns come into focus when we look at the most recent Alzheimer’s Association report at https://vist.ly/57vns, the Centers for Disease Control and Prevention at https://vist.ly/57vn2, and the National Institute on Aging at https://vist.ly/57vnd.
Across the country, the average age of onset continues to differ between men and women. Women are diagnosed later, often in their early eighties, while men tend to receive a diagnosis slightly earlier, often in their late seventies. This pattern is consistent with the national gender distribution showing that nearly two thirds of Americans living with Alzheimer’s are women, a figure confirmed in the 2024 Alzheimer’s Association report at https://vist.ly/57vn7 (alz.org in Bing). Researchers attribute this difference partly to longevity but also to biological factors such as the influence of the APOE ε4 gene, which appears to affect women more strongly. The National Institute on Aging discusses these biological differences at https://vist.ly/57vnb.
When we shift from gender to geography, the state by state picture becomes clearer. States with older populations naturally show higher percentages of residents living with Alzheimer’s. Florida, Pennsylvania, West Virginia, and Maine consistently appear at the top of the prevalence tables, while states with younger populations such as Utah and Alaska appear at the lower end. These patterns are visible in the Alzheimer’s Association’s state data tables at https://vist.ly/57vn6 (alz.org in Bing). The differences do not reflect higher or lower risk but instead mirror the age structure of each state. In states where a larger share of residents are over sixty five, the proportion of people living with Alzheimer’s rises accordingly. In states with younger populations, the percentage naturally falls.
When comparing the percentage of each state’s population living with Alzheimer’s versus those without, the national average remains close to one in nine adults over sixty five. This ratio is consistent across the CDC’s Healthy Aging Data Portal at https://vist.ly/57vnj and the Alzheimer’s Association’s national summary. The contrast becomes more pronounced in states with rapidly aging populations, where the proportion of older adults is growing faster than the national average. These demographic shifts influence everything from caregiver needs to healthcare planning.
A broader comparison helps place Alzheimer’s in context. When we look at Alzheimer’s disease alone versus all other dementias combined, Alzheimer’s remains the dominant cause. The remaining cases include vascular dementia, Lewy body dementia, frontotemporal disorders, and mixed dementias. The CDC’s dementia overview at https://vist.ly/57vng confirms that mixed dementia is more common than previously recognized, meaning many individuals live with overlapping Alzheimer’s and vascular changes. Even with these overlaps, Alzheimer’s remains the single largest contributor to dementia diagnoses.
Several factors help explain the variations seen across gender, geography, and dementia type. Age remains the strongest known risk factor, which is why states with older populations show higher prevalence. Longevity differences between men and women contribute to the gender gap, but so do biological and hormonal factors that researchers continue to explore. Social determinants of health also play a role. Older Black Americans are about twice as likely to have Alzheimer’s or other dementias as older White Americans, a pattern documented by the CDC at https://vist.ly/57vn8 (cdc.gov in Bing). This means that states with larger Black populations may see higher dementia prevalence even when adjusting for age. Education, access to healthcare, cardiovascular health, and lifetime stress exposure all influence these numbers.
The newest figures also highlight the growing impact on caregivers. More than eleven million Americans provide unpaid care for someone living with Alzheimer’s or another dementia, contributing billions of hours of support each year. These caregiving patterns vary by state depending on available services, cultural norms, and access to diagnostic resources. The Alzheimer’s Association’s caregiving data at https://vist.ly/57vna (alz.org in Bing) provides a deeper look at these differences.
Taken together, the latest data shows a landscape shaped by age, gender, biology, and state demographics.

06/01/2026

NutraMD Nasal Defense Spray and Alzheimer’s Disease: Clearing Up the Confusion

Sometimes new products sound hopeful, especially when we’re caring for someone we love. Here’s what I found after taking a closer look at NutraMD Nasal Defense Spray and Alzheimer’s disease, and what science says, in simple, calm language families can trust.
Every caregiver knows how quickly new products appear online, each one sounding like the answer we have been waiting for. When a nasal spray like NutraMD Nasal Defense begins circulating in conversations about Alzheimer’s disease, it is natural to pause and wonder whether there is something real behind the claim.
NutraMD Nasal Defense Spray is an iodine based nasal cleanser. It is sold as a gentle way to clean the nasal passages. The product pages describe it as a daily hygiene spray, not as a treatment for memory loss or dementia. You can see an example of the product description here: https://vist.ly/5653b (search for “Nutramd Iodine Nasal Spray”).
The idea that a nasal spray might help the brain comes from early scientific studies, but these studies involve very different products. Researchers at Texas A&M University created a special laboratory spray that carries tiny biological particles. In aging mice, this experimental spray reduced inflammation and improved memory. You can read about this research here: https://vist.ly/5642y (search for “Scientists reverse brain aging with a nasal spray Texas A&M”). A second summary of the same work is here: https://vist.ly/56534 (search for “A simple nasal spray may help reverse brain aging”).
These sprays are not sold in stores. They are not the same as NutraMD. They have not been tested in people with Alzheimer’s disease. They are early scientific tools, not treatments.
Right now, there is no evidence that NutraMD Nasal Defense Spray helps with Alzheimer’s disease. There are no human studies showing that it affects memory, thinking, or the progression of dementia. The claim that it is an effective spray for Alzheimer’s disease is not supported by research.
Families deserve clear information. If you are exploring new ideas or wondering about products you see online, it can help to talk with a healthcare professional who understands the person you care for. Reliable information about Alzheimer’s disease is available at: https://vist.ly/5653d https://vist.ly/56537
Hope is powerful, and so is clarity. NutraMD Nasal Defense Spray is a nasal cleanser. At this time, it is not a treatment for Alzheimer’s disease.

05/29/2026

Discussing Alzheimer’s Concerns with Loved Ones

There is a moment in many families when a quiet truth begins to take shape, long before anyone says it aloud. You notice small things at first, the kind that could be brushed away as stress or distraction. Yet something inside you whispers that these changes feel different, and that whisper grows heavier with time. When you reach the point where concern outweighs hesitation, the question becomes how to open a conversation that feels tender, respectful, and safe for the person you love.
Beginning this dialogue is less about delivering information and more about creating a space where dignity stays intact. It helps to approach your loved one during a calm moment, when the day is unhurried and emotions are steady. The tone you bring matters as much as the words themselves. When you speak from a place of care rather than alarm, the conversation becomes an act of protection rather than confrontation. You might start by sharing what you have noticed in a gentle, observational way, as if you are placing a small stone on the table between you both rather than handing them a heavy weight to carry alone. This keeps the focus on shared experience rather than blame or fear.
Many people feel vulnerable when their memory begins to shift, even if they cannot name what is happening. They may already sense that something is changing and are waiting for someone they trust to acknowledge it with kindness. When you frame the idea of a medical evaluation to bring clarity and support, rather than as a judgment, it becomes easier for them to hear. You are not telling them what is wrong; you are inviting them into a process that can offer understanding and relief. Sometimes the most reassuring thing you can say is that you will walk beside them through every step.
It can also help to remind them that memory changes have many possible causes, some of which are treatable. This softens the fear that an evaluation automatically leads to a single conclusion. What you are offering is not a label but an opportunity to understand what the brain is trying to communicate. When the conversation is framed this way, it becomes less about loss and more about caring for their well being.
If your loved one reacts with worry or resistance, it does not mean the conversation has failed. It simply means the topic touches a tender place. You can pause, breathe, and return to it another day. What matters most is that you remain steady and compassionate, showing them that your intention is rooted in love. Over time, your calm presence can help them feel safe enough to consider the next step.
Opening this door is never easy, yet it is one of the most loving acts a caregiver can offer. You are not pushing them toward a diagnosis; you are guiding them toward understanding, comfort, and support. In doing so, you are reminding them that they are not facing these changes alone.

05/28/2026

The Many Faces of Dementia: Why Only a Few Are Seen, and So Many Are Silent

Dementia is often spoken about as if it were a single shadow that falls over a person’s life, but the truth is far more complex and far more human. There are many types of dementia, dozens, in fact, each shaped by different changes in the brain, each affecting people in its own way. Yet only a few ever seem to make their way into everyday conversation. Alzheimer’s disease, vascular dementia, Lewy body dementia, and frontotemporal dementia tend to dominate the spotlight, while the others remain almost invisible, tucked away in medical journals or whispered about only in specialist clinics.
Part of the reason is familiarity. Alzheimer’s has become the face of dementia because so many families have lived through it. When a condition touches millions, it becomes part of the cultural vocabulary. People recognize the signs, the stories, the heartbreak. The lesser-known types, like corticobasal degeneration, posterior cortical atrophy, or Creutzfeldt-Jakob disease, are rarer, harder to diagnose, and often misunderstood. They don’t show up in movies or fundraising campaigns. They don’t have the same public awareness or advocacy behind them. They remain in the shadows, even though the people living with them deserve just as much understanding and compassion.
Another reason is that dementia itself is frightening. It forces us to confront the fragility of memory, identity, and connection. Talking about one well-known form is already emotionally heavy; acknowledging the full spectrum can feel overwhelming. Families often cling to the label they’re given because it offers a sense of direction, even if it doesn’t capture the whole picture. The medical world, too, sometimes struggles with the complexity of the different types of dementia. Symptoms overlap and diagnoses can shift. What begins as one suspected type may evolve into another as the disease progresses. In that uncertainty, the quieter forms of dementia are easily overlooked.
Behind every type, common or rare, is a person trying to hold onto themselves, and a family trying to hold onto them. The labels matter less than the lived experience: the moments of clarity, the moments of confusion, the tenderness, the grief, the unexpected flashes of humor or love that still break through. When we talk only about the most familiar forms, we unintentionally narrow the space for others to be seen. We leave some families feeling isolated, as if their version of dementia doesn’t “fit” the story the world expects.
The truth is that dementia is not one story. It is thousands of stories, each with its own texture and rhythm. Some unfold slowly, others with devastating speed. Others affect memory first, while in some cases, vision, language, movement, or personality is affected. There can be variations in when different types of dementia begin in middle age, long before anyone expects them. There are other types of dementia that are so rare even seasoned clinicians may only encounter them a handful of times in their careers. Yet every one of them reshapes life.
Talking about all types of dementia, openly, honestly, and with heart, does more than raise awareness. It widens the circle of empathy. It reminds us that no one’s experience is too rare or too complicated to matter. It encourages families to seek answers, to ask questions and to push for better research and better care. It helps us see the people behind the diagnoses, not as a collection of symptoms but as whole human beings still deserving of dignity, patience, and love.

05/27/2026

The FDA’s Approval of the Elecsys pTau181 Blood Test

The U.S. Food and Drug Administration has now approved the Elecsys pTau181 blood test, and this moment represents a quiet but meaningful shift in how families and clinicians can approach early cognitive concerns. For many years, the path to understanding possible Alzheimer’s changes has relied on tools that were invasive, expensive, or difficult to access. With this approval, a simple blood draw can now offer early clarity, especially in primary care settings where most people first share their worries. The FDA announcement can be found directly at https://vist.ly/55jzn.
This test measures phosphorylated tau 181, known as pTau181, a protein closely tied to Alzheimer ’s-related changes in the brain. When the level of this protein falls below a specific threshold, the result helps clinicians determine that a person is unlikely to have amyloid-related Alzheimer’s pathology. That single insight can redirect the diagnostic process, allowing families to explore other causes of cognitive symptoms without immediately moving toward PET scans or lumbar punctures. Information about the test from Roche Diagnostics, the manufacturer, is available at https://vist.ly/55jzj.
What makes this approval especially significant is that the Elecsys pTau181 test is the first blood based biomarker cleared for use in primary care. Until now, biomarker testing for Alzheimer’s has largely been limited to specialty neurology clinics, creating delays and barriers for many people seeking answers. With this new pathway, primary care clinicians can begin offering a minimally invasive, widely accessible tool that supports earlier understanding and more appropriate referrals.
The test is intended for adults fifty five and older who are experiencing signs or symptoms of cognitive decline. It does not diagnose Alzheimer’s disease on its own, but it does help identify who is unlikely to have Alzheimer ’s-related amyloid changes. That clarity can shorten the time it takes to find the true source of symptoms and can help neurologists focus their attention on those who most need advanced evaluation. More details about clinical use can be found at the Alzheimer’s Association website, https://vist.ly/55jzw.
Studies show that the Elecsys pTau181 test can rule out Alzheimer ’s-related amyloid pathology with a negative predictive value of 97.9 percent, offering strong reassurance when the result is negative. Combined with the simplicity of a blood draw, this reliability signals a shift toward earlier, more equitable access to cognitive assessment.
As this test becomes integrated into health systems across the country, supported by thousands of existing Roche laboratory instruments already in place, families may begin to experience a diagnostic process that feels less intimidating, less invasive, and more responsive to the earliest whispers of change.

05/26/2026

How Alzheimer’s Diagnostic Steps Fit Together

The path toward understanding cognitive change has always felt like a maze for families, especially when the earliest signs are subtle or confusing. The approval of the Elecsys pTau181 blood test adds a new doorway into that maze, but it becomes even more meaningful when seen within the full landscape of Alzheimer’s diagnostics. Each step offers a different kind of information, and together they create a clearer picture of what is happening beneath the surface.
The journey often begins in a primary care office, where a person or family member shares concerns about memory, language, or daily functioning. This first conversation is where the Elecsys pTau181 test now lives. A clinician can order the blood test through laboratories that use Roche’s Elecsys platform, described at https://vist.ly/55fup. When the result shows low levels of phosphorylated tau 181, it suggests that Alzheimer’s related amyloid pathology is unlikely. That single insight can redirect the entire process, allowing families to explore other medical explanations such as thyroid changes, vitamin deficiencies, sleep disorders, medication effects, or depression. The FDA announcement describing this new testing pathway is available at https://vist.ly/55fuq.
If the blood test does not rule out Alzheimer’s related changes, the next steps often move toward more specialized evaluation. Cognitive testing with a neurologist or neuropsychologist helps identify patterns in memory, attention, language, and problem solving. These patterns can hint at whether the brain is experiencing Alzheimer’s type changes or something different. Information about cognitive testing and clinical evaluation can be found at the Alzheimer’s Association website, https://vist.ly/55fur.
When deeper clarity is needed, imaging becomes part of the picture. MRI scans help rule out strokes, tumors, or structural changes. PET scans can detect amyloid or tau proteins directly, though they are expensive and not always covered by insurance. Cerebrospinal fluid testing through lumbar puncture can measure amyloid and tau levels with high accuracy. These tools have long been the gold standard, but they are not always accessible, which is why the arrival of a blood based biomarker in primary care is so meaningful.
Each step in this pathway carries its own purpose. The blood test offers early direction. Cognitive testing reveals functional patterns. Imaging and cerebrospinal fluid analysis provide biological confirmation. Together, they create a layered, compassionate approach that helps families understand what is happening and what comes next. As more blood based biomarkers become available, the hope is that this pathway will feel less overwhelming and more supportive, offering answers earlier and with greater ease.

05/26/2026

How Alzheimer’s Diagnostic Steps Fit Together

The path toward understanding cognitive change has always felt like a maze for families, especially when the earliest signs are subtle or confusing. The approval of the Elecsys pTau181 blood test adds a new doorway into that maze, but it becomes even more meaningful when seen within the full landscape of Alzheimer’s diagnostics. Each step offers a different kind of information, and together they create a clearer picture of what is happening beneath the surface.
The journey often begins in a primary care office, where a person or family member shares concerns about memory, language, or daily functioning. This first conversation is where the Elecsys pTau181 test now lives. A clinician can order the blood test through laboratories that use Roche’s Elecsys platform, described at https://vist.ly/55fsw. When the result shows low levels of phosphorylated tau 181, it suggests that Alzheimer’s related amyloid pathology is unlikely. That single insight can redirect the entire process, allowing families to explore other medical explanations such as thyroid changes, vitamin deficiencies, sleep disorders, medication effects, or depression. The FDA announcement describing this new testing pathway is available at https://vist.ly/55fsz.
If the blood test does not rule out Alzheimer’s related changes, the next steps often move toward more specialized evaluation. Cognitive testing with a neurologist or neuropsychologist helps identify patterns in memory, attention, language, and problem solving. These patterns can hint at whether the brain is experiencing Alzheimer’s type changes or something different. Information about cognitive testing and clinical evaluation can be found at the Alzheimer’s Association website, https://vist.ly/55ft6.
When deeper clarity is needed, imaging becomes part of the picture. MRI scans help rule out strokes, tumors, or structural changes. PET scans can detect amyloid or tau proteins directly, though they are expensive and not always covered by insurance. Cerebrospinal fluid testing through lumbar puncture can measure amyloid and tau levels with high accuracy. These tools have long been the gold standard, but they are not always accessible, which is why the arrival of a blood based biomarker in primary care is so meaningful.
Each step in this pathway carries its own purpose. The blood test offers early direction. Cognitive testing reveals functional patterns. Imaging and cerebrospinal fluid analysis provide biological confirmation. Together, they create a layered, compassionate approach that helps families understand what is happening and what comes next. As more blood based biomarkers become available, the hope is that this pathway will feel less overwhelming and more supportive, offering answers earlier and with greater ease.

Alzheimer's Support, LLC

06/19/2026

06/18/2026

06/17/2026

06/16/2026

06/01/2026

05/29/2026

05/28/2026

05/27/2026

05/26/2026

05/26/2026

Address

Telephone

Website

Alerts

Contact The Business

Shortcuts

Share